Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622142 | 1.00 | KDM4E (0.47) | KDM4ELMNAHSD17B10NPSR1ELANE | |
| SCHEMBL2622141 | 0.89 | ELANE (0.48) | ELANE | |
| SCHEMBL2622087 | 0.89 | ELANE (0.48) | ELANE | |
| SCHEMBL1933817 | 0.89 | ELANE (0.48) | ELANE | |
| SCHEMBL2622091 | 0.89 | ELANE (0.46) | ELANE | |
| SCHEMBL2622107 | 0.89 | ELANE (0.46) | ELANE | |
| SCHEMBL2114028 | 0.89 | ELANE (0.46) | ELANE | |
| SCHEMBL2622140 | 0.89 | ELANE (0.46) | ELANE | |
| SCHEMBL2622182 | 0.88 | ELANE (0.45) | KDM4EELANETSHR | |
| SCHEMBL2114288 | 0.88 | ELANE (0.45) | KDM4EELANETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | KDM4E 2828/4885LMNA 767/4885HSD17B10 4218/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | KDM4E 2828/4885LMNA 767/4885HSD17B10 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.